🔎 Trials Near Me

Akèy › Kansè renn (Kasinom selil renn) › Ohio › Columbus

Etid klinik pou Kansè renn (Kasinom selil renn) nan Columbus, OH

13 etid pou Kansè renn (Kasinom selil renn) ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • The Mark H Zangmeister Center, Columbus
  • ak 8 plis
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • ak 11 plis
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 12 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT04981509

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Ap rekriteEtid obsèvasyon
  • The Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06863311

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05327686

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Ap rekriteFaz 3
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06661720

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Ap rekriteFaz 1
  • Xencor Investigative Site, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT05433142

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Ap rekriteFaz 1/2
  • James Cancer Hospital and Solove Research Institute, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT03972657

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Ap rekriteFaz 1
  • Ohio State University, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT06026410

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • The Ohio State University Wexner Medical Center, Columbus
Tout laj · Tout sèks · Mizajou Mar 9, 2026 · NCT04792463

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Ap rekriteFaz 1/2
  • The Ohio State University, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT06682793

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Ap rekriteFaz 3
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT04510597

Etid Kansè renn (Kasinom selil renn) nan lòt vil

Lòt etid nan Columbus

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.